suPAR MonographNEW - ON THE BASIS OF MORE THAN 400 PUBLISHED ARTICLES ON suPAR IN PubMed, A suPAR MONOGRAPH HAS BEEN WRITTEN.Here you can find a short summary of the research done on suPAR within 12 groups of disease areas, and see how the suPAR level is affected within each kind of disease.

to find all our scientific videos including selected presentations from our suPAR Symposias.

KEY SUPAR PUBLICATIONS

September 2, 2016:"suPAR in acute care: A strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study" was publisehd online in EMJ, Emergency Medical Journal in September 2016.

The study included 4343 consecutively admitted patients from the AMU at a large Danish university hospital (Hvidovre).

The conclusion is again, that in an unselected population of acute medical patients;"A high suPAR level upon admission to the AMU is a marker of severe disease and increased risk of readmission and mortality after adjusting for all other risk factors .... and suPAR adds information to established prognostic indicators".

Patients with low suPAR levels have low risk of readmission and mortality, while patients with high suPAR levels have a high risk of adverse events.

November 10, 2015:A study in the New England Journal of Medicine published on November 5 shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.

Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.

The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease."We can now stratify people according to their risk of developing kidney disease using suPAR levels" said Dr. Salim Hayek, first author of the study.

The study is even a significant breakthrough in preventive medicine. Also diabetes patients, of which about one-third develop Diabetic Kidney Disease, can now be helped."This will help risk-stratify patients with diabetes on their risk of future kidney disease" explains Jochen Reiser, senior author of the NEJM study.

Results are based upon research using the suPARnostic® products from ViroGates.

Data are based on all medical patients coming to the Emergency Room (ER), and are thus very representative for the most common diseases seen in any Emergency Room incl. not only bacterial or viral infections but also CVD, cardiac cases, lung diseases and comorbidities.In this wide cohort, suPAR (ELISA) testing gives an 0.85 AUC value for prognosing survival, which is much stronger than CRP and the prognosis provided in the DEPT Triage system.

Data shows that the current Danish Emergency Process triage system needs to be improved with a prognostic biomarker evaluation - and suPAR is the best choice!

The conclusion is clear: "In unselected patients admitted to an Emergency Department, suPAR is an independant marker of short-term mortality. suPAR could potentially help clinicians in the initial risk assessment of acutely admitted patients".